8-K: Calidi Biotherapeutics Forms Scientific Advisory Board

Calidi Biotherapeutics announced the formation of a Scientific Advisory Board to guide the development of its RedTail platform and advance CLD-401 into clinical trials.

Summary

• Calidi Biotherapeutics established a new Scientific Advisory Board (SAB) on October 22, 2025, to support the development of its RedTail platform and advance CLD-401 into clinical trials.
• The RedTail platform is a groundbreaking approach to genetic medicines utilizing an enveloped form of vaccinia virus, genetically engineered to avoid immune clearance and allow systemic delivery of genetic medicine payloads to disease sites.
• CLD-401, the first lead candidate from the RedTail platform, is designed to home to metastatic sites, replicate only in tumor cells, induce an immune priming event, and express high levels of IL-15 superagonist in the tumor microenvironment.
• The founding members of the SAB include Mace L. Rothenberg, MD, Dmitriy Zamarin MD, PhD, John Wrangle, MD, MPH, and David T. Curiel, MD, PhD, all recognized experts in drug development, translational research, virotherapy, and immunotherapy.
• An updated company presentation was made available on Calidi Biotherapeutics' website on October 24, 2025.

Sentiment

Score: 8

Explanation: The establishment of a highly qualified Scientific Advisory Board is a significant positive step for a clinical-stage biotech company, indicating a strengthened commitment to scientific rigor and strategic development. The expertise of the board members, particularly those with extensive drug development and regulatory experience, significantly de-risks the scientific and clinical pathway for the RedTail platform and CLD-401. While financial risks are noted, the scientific advancement is a strong positive.

Positives

• Formation of a Scientific Advisory Board composed of internationally esteemed experts with deep expertise in drug development, translational research, virotherapy, and immunotherapy.
• The SAB's insight and experience are expected to guide the efficient development of CLD-401 into the clinic and advance the utility of the RedTail platform.
• CLD-401, the lead candidate from the RedTail platform, is designed with multiple mechanisms of action including systemic delivery, tumor-specific replication, immune priming, and IL-15 superagonist expression.
• The RedTail platform represents a groundbreaking approach to genetic medicines, utilizing an engineered enveloped vaccinia virus to avoid immune clearance and target genetic medicine payloads to disease sites.

Risks

• The company may not be able to raise sufficient capital to support its current and anticipated clinical trials.
• Early results of clinical trials do not necessarily predict final results, and clinical outcomes may materially change after more comprehensive data review.
• The company may not receive FDA approval for some or all of its therapeutic candidates.
• Other risks and uncertainties are set forth in the section entitled Risk Factors and Cautionary Note Regarding Forward-Looking Statements in the company's annual report filed with the SEC on Form 10-K on March 31, 2025.

Future Outlook

The company anticipates that the Scientific Advisory Board's insights and experience will help guide the efficient development of CLD-401 into the clinic and advance the utility of the RedTail platform in oncology and beyond. The lead candidate, CLD-401, is currently in IND-enabling studies and targets non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need.

Management Comments

• "We are excited to have such an internationally esteemed group of advisors working with the company. We believe their insight and experience will help guide the efficient development of CLD-401 into the clinic and advance what the utility of the RedTail platform in oncology and beyond." Eric Poma, Ph.D., CEO of Calidi.

Industry Context

The formation of a Scientific Advisory Board with experts in virotherapy, immunotherapy, and oncology aligns with the broader industry trend of leveraging specialized scientific expertise to accelerate the development of complex genetic medicines and oncolytic viruses for cancer treatment. This move positions Calidi to potentially enhance its competitive standing in the rapidly evolving field of targeted genetic therapies, particularly for metastatic cancers, by bringing in seasoned professionals who have contributed to significant drug approvals and translational research.

Stakeholder Impact

• Shareholders: Potential for increased confidence due to strengthened scientific guidance and accelerated development of therapeutic candidates, potentially leading to future value creation.
• Patients: Potential for new, targeted genetic medicines for difficult-to-treat cancers like non-small cell lung cancer and head and neck cancer.
• Employees: Enhanced scientific direction and support for research and development efforts.
• Regulatory Authorities: A strong SAB can lend credibility to the company's scientific approach and clinical trial designs.

Next Steps

• Further develop the RedTail platform.
• Advance CLD-401 into the clinic.
• Conduct IND-enabling studies for CLD-401.

Key Dates

Recommendation

The formation of a Scientific Advisory Board comprised of highly respected and experienced leaders in drug development, oncology, and virotherapy is a strong positive catalyst for Calidi Biotherapeutics. This move significantly enhances the company's scientific credibility and strategic direction, which is crucial for a clinical-stage biotech. The expertise brought by the SAB members, particularly those with a track record of successful drug development and regulatory approvals, can accelerate the efficient advancement of the RedTail platform and CLD-401 into the clinic. While the company faces inherent risks common to biotech, including capital requirements and clinical trial outcomes, this development suggests a strengthened foundation for future growth and potential value creation, making it an attractive opportunity for long-term investors.

Keywords

Calidi Biotherapeutics, CLDI, Scientific Advisory Board, RedTail platform, CLD-401, Genetic Medicine, Oncolytic Virus, Virotherapy, Oncology, Biotechnology, Drug Development, Clinical Trials, Immunotherapy, Cancer Treatment